NeuroVive Pharmaceutical AB is a Sweden-based biotechnology company engaged in mitochondrial medicine. The Company’s primary projects are NeuroSTAT and KL1333. NeuroSTAT aims to prevent moderate to severe traumatic brain injury, while KL1333 aims to treat genetic mitochondrial disease. NeuroSTAT is in clinical phase II and KL1333 is in clinical phase I. The Company possesses the research and development (R&D) portfolio, which consists of several late stage research programs in such areas as genetic mitochondrial disorders, cancer and metabolic diseases, among others. In R&D work the Company partners with Skane University Hospital in Sweden, Copenhagen University Hospital in Denmark, University of Pennsylvania in the United States, as well as with a range of contract research organizations.